Ironwood Pharmaceuticals shares surge 36.20% premarket after Citizens upgrades to Outperform and 2026 Linzess sales guidance boosts optimism.

Ironwood Pharmaceuticals surged 36.20% in premarket trading following a Citigroup upgrade to "Market Outperform" with a $8.00 price target (87% upside from its $4.27 level) and revised 2026 financial guidance. The upgrade cited the resolution of LINZESS headwinds, with the drug projected to generate $1.125–$1.175 billion in U.S. net sales in 2026 (up from $860–$890 million in 2025), alongside strong free cash flow of 10% to fund debt and pipeline development for apraglutide. Additional catalysts included FDA approval of Linzess for pediatric IBS-C and a $12.5 million settlement with Ferring, reducing litigation uncertainty. These developments reinforced investor confidence in the company’s improved financial trajectory and long-term value.